卡培他滨联合沙利度胺对晚期结直肠癌节拍化疗的效果

Abstract
Figure/Table
References (15)
Related Citation (1)

Download: PDF (0 KB) HTML (30 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo investigate the clinical effect of Capecitabine combined with Thalidomide in the metronomic chemotherapy of advanced colorectal cancer.MethodsFrom February 2016 to March 2016,56 patients who diagnosed with advanced colorectal cancer treated in our hospital were selected as the research objects,and they were divided into the combination group(n=30)and chemotherapy group(n=26)according to random number table method.The combination group were treated with Capecitabine combined with Thalidomide.In the chemotherapy group,Oxaliplatin was injected intravenously on the first day and Leucovorin was injected intravenous from second to fifth days,and 20 days for one cycle.The effects of chemotherapy,therapeutic effect and adverse reactions were compared between the two groups.ResultsThe disease control rate of the patients in the combination group was 76.67%,and in the chemotherapy group was 53.85%,the control rate of the disease was compared between the two groups,and the difference was statistically significant(P＜0.05).The total effective rate of treatment was 80.00%,which was significantly higher than 34.62%in the chemotherapy group,and the difference was statistically significant(P＜0.05).The total incidence of adverse reactions(33.33%)in the combination group was significantly lower than that in the chemotherapy group(92.31%),and the difference was statistically significant(P＜0.05).ConclusionCapecitabine combined Thalidomide in the treatment of advanced colorectal cancer has remarkable efficacy,high safety and low adverse reaction rate,so it is worth using in clinical.

Key words： Capecitabine Thalidomide Advanced colorectal cancer Metronomic chemotherapy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Zhi

Cite this article:

CHEN Zhi. Metronomic chemotherapy effect of Capecitabine combined with Thalidomide in the chemotherapy of advanced colorectal cance[J]. 中国当代医药, 2017, 24(35): 50-52.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I35/50

[1]	李道娟，李倩，贺宇彤.结直肠癌流行病学趋势[J].肿瘤防治研究，2015，42（3）:305-310.
[2]	王贵玉.结直肠癌NCCN、NICE及ESMO指南的对比分析和解读[J].中国癌症杂志，2015，25（11）:849-853.
[3]	钟武，张磊昌，钟世彪，等.结直肠癌患者术前CEA、CA19-9浓度与临床病理特征及预后的关系[J].中国普通外科杂志，2015，24（4）:499-504.
[4]	Cortejoso L，López-Fernández LA.Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients[J].Pharmacogenomics，2016，13（10）:1173-1191.
[5]	徐征，庞冬，刘卓，等.结直肠癌术后患者对手术治疗决策满意度的影响因素分析[J].中华护理杂志，2015，50（12）:1484-1488.
[6]	付林，秦锴.替吉奥与卡培他滨术前新辅助化疗对结直肠癌外周血细胞角蛋20核糖核酸表达的影响[J].中国临床药理学杂志，2015，82（3）:187-189.
[7]	刘潇衍，孙永琨，尼露排·阿布都热黑依木，等.重组人血管内皮抑制素和沙利度胺联合化疗治疗转移性结直肠癌的临床观察[J].临床肿瘤学杂志，2015，65（1）:48-52.
[8]	潘维，杨虎.雷替曲塞联合奥沙利铂与5-氟尿嘧啶、亚叶酸钙联合奥沙利铂治疗转移性结直肠癌的疗效比较[J].现代医院，2016，16（4）:471-473.
[9]	中华人民共和国卫生和计划生育委员会医政医管局.结直肠癌诊疗规范[J].中华外科杂志，2015，53（12）:1177-1191.
[10]	郭金萍，朱琳，苏银霞，等.结直肠癌危险因素及临床流行病学特征研究[J].实用癌症杂志，2015，13（4）:544-546.
[11]	李文桦.晚期结直肠癌的化疗进展[J].中国癌症杂志，2015，14（4）:378-382.
[12]	高春辉，郑晓库.以卡培他滨为基准的新辅助化疗对中国人进展期胃癌疗效的Meta分析[J].解放军医学院学报，2015，29（8）:781-785.
[13]	韦青，王晰程，沈琳.二氢嘧啶脱氢酶与氟尿嘧啶类药物不良反应及疗效相关性[J].癌症进展，2016，14（7）:608-612.
[14]	裴丽，罗艳，黄显金，等.沙利度胺的临床新应用与不良反应研究概述[J].中国药师，2016，19（5）:977-980.
[15]	王年飞，陈振东.沙利度胺治疗实体瘤的现状与进展[J].临床肿瘤学杂志，2015，22（3）:276-281.